SciClone Pharmaceuticals

SciClone Pharmaceuticals, Inc. (SciClone ) is a global specialty pharmaceutical company with a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. SciClone’s proprietary lead product, ZADAXIN (thymalfasin), may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as an immune system enhancer, according to the local regulatory approvals. The Company has successfully in-licensed and commercialized products with the potential to become future market leaders and to drive the Company's long-term growth, including DC Bead, a novel treatment for liver cancer, approved in China, and several other products in late-stage development in China. 

Type
Public
HQ
Foster City, US
Founded
1989
Size (employees)
570 (est)-3%
SciClone Pharmaceuticals was founded in 1989 and is headquartered in Foster City, US

SciClone Pharmaceuticals Office Locations

SciClone Pharmaceuticals has an office in Foster City
Foster City, US (HQ)
900 950 Tower Ln

SciClone Pharmaceuticals Data and Metrics

SciClone Pharmaceuticals Financial Metrics

SciClone Pharmaceuticals's revenue was reported to be $160.1 m in 2016
USD

Revenue (Y, 2016)

160.1 m

Revenue growth (Y, 2015 - Y, 2016), %

2%

Gross profit (Y, 2016)

137.2 m

Gross profit margin (Y, 2016), %

86%

Net income (Y, 2016)

30.7 m

EBIT (Y, 2016)

33.2 m

Market capitalization (28-Jun-2017)

563.9 m

Closing share price (28-Jun-2017)

10.9

Cash (31-Dec-2016)

134.4 m
SciClone Pharmaceuticals's current market capitalization is $563.9 m.
USDFY, 2013FY, 2014FY, 2015Y, 2016

Revenue

127.1 m134.8 m157.3 m160.1 m

Revenue growth, %

6%17%2%

Cost of goods sold

22.3 m22.9 m

Gross profit

134.9 m137.2 m

Gross profit Margin, %

86%86%

Operating expense total

127.3 m126.9 m

EBIT

10.4 m26 m29.9 m33.2 m

EBIT margin, %

8%19%19%21%

Net Income

11 m25.2 m29.5 m30.7 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

85.8 m86.2 m101.4 m134.4 m

Accounts Receivable

40.3 m

Inventories

15.2 m10.7 m11 m16.6 m

Current Assets

143.4 m140.2 m168.5 m195.7 m

PP&E

843 k1.8 m2.7 m2 m

Goodwill

35.4 m34.5 m33 m30.8 m

Total Assets

180.2 m181.8 m216.6 m241.9 m

Accounts Payable

7.2 m5.3 m4.5 m3.6 m

Current Liabilities

33.6 m26.4 m36.8 m26.4 m

Additional Paid-in Capital

278.3 m287.1 m296.1 m304.6 m

Retained Earnings

(136 m)(135.1 m)(118.5 m)(87.8 m)

Total Equity

146.6 m155.3 m179.7 m215.4 m

Financial Leverage

1.2 x1.2 x1.2 x1.1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

11 m25.2 m29.5 m30.7 m

Depreciation and Amortization

860 k852 k931 k985 k

Accounts Receivable

(4.2 m)(3.3 m)306 k(2.4 m)

Inventories

(4.7 m)5.9 m1.4 m(3 m)

Accounts Payable

(652 k)(5.5 m)(2.3 m)(3.1 m)

Cash From Operating Activities

9.5 m27.6 m32.5 m34.5 m

Purchases of PP&E

(324 k)(1.5 m)(1.8 m)(648 k)

Cash From Investing Activities

55 k(6.2 m)(9 m)(3.4 m)

Cash From Financing Activities

(8.4 m)(20.8 m)(8.4 m)1.9 m
USDY, 2016

Revenue/Employee

271.3 k

Financial Leverage

1.1 x

SciClone Pharmaceuticals Market Value History

SciClone Pharmaceuticals Company Life and Culture

You may also be interested in